Good run continues for Imugene with $1.85M R&D tax incentive

By Megan Graham. Published at Nov 9, 2018, in Biotech

Clinical-stage immuno-oncology company, Imugene (ASX:IMU), has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme.

The receipt of the $1.85 million in additional funding will go towards IMU’s commercial and clinical milestones, with the company experiencing its most significant period of R&D expenditure in the September 2018 quarter — when R&D outflows totalled $1.65 million.

The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.

The Australian government’s R&D tax incentive encourages companies to engage in R&D programs by providing a refundable tax offset of up to 43.5% for eligible activities.

IMU has a highly experienced leadership team, including Chairperson Paul Hopper — who led small cap Viralytics to a $502.4 million buyout by pharmaceutical giant, Merck & Co (NYSE:MRK) earlier this year.

In June this year, IMU signed an exclusive world-wide licence for the entire body of cancer vaccine work and intellectual property developed by Professor Pravin Kaumaya of the Ohio State University Wexner Medical Centre and Dr Tanios Bekaii Saab of the Mayo Clinic.

The deal transforms IMU’s position from a one product, one-trial focused small cap to a substantial intellectual property estate. In total, it now holds six patent families, comprising 16 patents or pending applications for a large range of B-cell peptide and cancer vaccines.

IMU’s flagship HER-Vaxx drug candidate is currently in Phase I/b, with results expected in the near-term.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn